Search research articles
Contact Us
Filters
Showing results (421-430 of 621) with videos related to
Page
of 63
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2011
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status
Eric Van Cutsem, Claus-Henning Köhne, István Láng, et al.
Cell Reports
|
September 8, 2015
Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR
Linara Gabitova, Diana Restifo, Andrey Gorin, et al.
Journal of Lipid Research
|
December 8, 2009
Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infection
Ronald W Clark, David Cunningham, Yang Cong, et al.
BJC Reports
|
November 8, 2024
Incidental finding of leukaemia in circulating tumour DNA- the importance of a molecular tumour board
Justin Mencel, Neha Rayarel, Paula Proszek, et al.
International Journal of Cancer
|
June 15, 2019
Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients
Francesco Sclafani, Sanna Hulkki Wilson, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2012
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)
Alice Dewdney, David Cunningham, Josep Tabernero, et al.
The Lancet. Oncology
|
April 30, 2013
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
Thomas Crosby, Christopher N Hurt, Stephen Falk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2019
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.
Blood Advances
|
June 23, 2023
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.
British Journal of Cancer
|
September 22, 2017
Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer
Francesco Sclafani, Gina Brown, David Cunningham, et al.
Page
of 63
Search research articles
Search
Showing results (421-430 of 621) with videos related to
Sort By:
Page
of 63
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2011
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status
Eric Van Cutsem, Claus-Henning Köhne, István Láng, et al.
Cell Reports
|
September 8, 2015
Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR
Linara Gabitova, Diana Restifo, Andrey Gorin, et al.
Journal of Lipid Research
|
December 8, 2009
Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infection
Ronald W Clark, David Cunningham, Yang Cong, et al.
BJC Reports
|
November 8, 2024
Incidental finding of leukaemia in circulating tumour DNA- the importance of a molecular tumour board
Justin Mencel, Neha Rayarel, Paula Proszek, et al.
International Journal of Cancer
|
June 15, 2019
Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients
Francesco Sclafani, Sanna Hulkki Wilson, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2012
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)
Alice Dewdney, David Cunningham, Josep Tabernero, et al.
The Lancet. Oncology
|
April 30, 2013
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
Thomas Crosby, Christopher N Hurt, Stephen Falk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2019
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.
Blood Advances
|
June 23, 2023
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.
British Journal of Cancer
|
September 22, 2017
Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer
Francesco Sclafani, Gina Brown, David Cunningham, et al.
Page
of 63